News | August 23, 2024
Nephro Care India reports 86.07% jump in PAT at Rs 4.41 crore during FY 23-24
Higher revenues backed by huge demand and expanding network contributed to the growth in bottom line
Higher revenues backed by huge demand and expanding network contributed to the growth in bottom line
Patni brings over 25 years of distinguished experience in the pharmaceutical industry
India Business grew by 11.9% YoY to Rs. 1196.2 crore
European markets now contribute 51% of our business revenue up from 43% in Q4 FY24 and 34% in Q1 FY24
Q1FY25 Revenue from Operations grew by 15% to Rs. 177 crore
Research & Development (R&D) investments for the quarter stood at Rs. 392.5 crore which is 6.3% of its revenues
Our centers are performing as expected or even better
The pharma market is showing encouraging signs of improvement, positioning us well for future growth
Pharmaceuticals and Consumer Health report higher sales (Fx & portfolio adj.) and lower earnings
The drugmaker's net profit slipped 26 per cent on-year to Rs 143.8 crore
Subscribe To Our Newsletter & Stay Updated
